eligibility_summary
Eligibility: Adults 18–65 with stable allergic asthma, episodic wheeze/SOB, FEV1 ≥70% predicted, positive methacholine (PC20 ≤16 mg/mL or PD20 ≤400 µg), positive skin-prick and allergen-induced early/late bronchoconstriction, able to consent/comply. Exclude: recent exacerbation/resp infection (<6 wks), other lung disease, prior c‑Kit inhibitor, anaphylaxis to biologics, maintenance asthma meds (intermittent SABA once weekly/PRN for exercise allowed), pregnancy/lactation or no contraception.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06592768: Double-blind, placebo-controlled, parallel-group Phase 1 trial in adults with allergic asthma using an allergen-challenge model. Intervention: briquilimab (JSP191), a humanized IgG1 monoclonal antibody, given subcutaneously, comparator: placebo. Mechanism of action: binds c-Kit (CD117) and blocks stem cell factor (SCF) signaling, leading to inhibition/depletion of c‑Kit–positive cells—most relevantly airway mast cells. Targets/pathways: mast cells and the SCF–c‑Kit pathway that supports mast-cell survival, activation, and degranulation, thereby aiming to reduce early and late allergic bronchoconstriction and airway hyperresponsiveness, potential impact on c‑Kit+ hematopoietic progenitors. Status: terminated due to sponsor priorities, not safety.